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ABSTRACT 
Objective: Symptomatic infections of the central nervous system (CNS) with JC 
polyoma virus (JCV) usually occur as a result of immunocompromise and manifest as 
progressive multifocal leukoencephalopathy (PML) or granule cell neuronopathy 
(GCN). After immune reconstitution, some of these cases may show long-term 
persistence of JCV and delayed clinical improvement despite inflammation. 
Methods: We followed four patients with multiple sclerosis, who developed 
natalizumab-associated PML or GCN with regard to JC viral load and JCV-specific T 
cell responses in the CNS. All of them experienced immune reconstitution 
inflammatory syndrome (IRIS), but in two cases JCV persisted more than 21 months 
after IRIS accompanied by delayed clinical improvement.   
Results: Persistence of JCV was associated with a lack of JCV VP1-specific T cell 
responses during immune reconstitution in one of the patients. Detailed analysis of 
the brain infiltrate in another patient with neuronal persistence of JCV revealed strong 
infiltration of CD8+ T cells and clonal expansion of activated CD8+ effector T cells with 
a CD4dimCD8+ phenotype, both exhibiting exquisite specificity for conserved epitopes 
of JCV large T antigen. However, clearance of JCV was not efficient, since mutations 
in the major capsid protein VP1 caused reduced CD4+ T cell responses against the 
identified JCV variant and subsequently resulted in a decline of CD8+ T cell 
responses after IRIS. 
Interpretation: Our findings suggest that efficient CD4+ T cell recognition of 
neurotropic JCV variants is crucial to support CD8+ T cells in combating JCV infection 
of the CNS. 
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INTRODUCTION 
JCV can cause different neurological disorders in states of immunocompromise such 
as AIDS but emerged recently also in patients under monoclonal antibody therapies 
including multiple sclerosis (MS) patients treated with natalizumab, an anti-VLA-4 
monoclonal antibody that prevents the migration of leukocytes through the blood-
brain-barrier.1-3 Infections of the CNS with JCV result in lytic destruction of 
oligodendrocytes or granule cell neurons leading to progressive multifocal 
leukoencephalopathy (PML) or granule cell neuronopathy (GCN), respectively.3-5 
Molecular characterization of PML- and GCN-associated JCV strains identified 
specific mutations particularly in the major capsid protein VP1, which may be 
associated with altered cellular tropism.6, 7 Until now there is no treatment for PML or 
GCN, and the only way to eliminate JCV efficiently from the CNS is to restore 
immune competence, e.g. by eliminating the monoclonal antibody in patients under 
monoclonal antibody therapy. This in turn can lead to PML or GCN immune 
reconstitution inflammatory syndrome (PML-IRIS, GCN-IRIS) that is characterized by 
massive influx of JCV-specific T cells, B cells and monocytes into the CNS at the site 
of JCV infection.8 However, a subgroup of PML patients shows an unusually slow 
drop of JCV copy numbers in the CNS despite immune reconstitution and 
development of IRIS.9, 10 
Although it is not yet fully understood, which components of the immune system are 
involved in resolution of JCV infection in the brain, there is increasing evidence that T 
cells play a key role in eliminating the virus in the CNS.11 However, controversy 
exists concerning the roles of CD4+ or CD8+ T cells. Earlier studies emphasized the 
importance of JCV-specific CD8+ T cell responses regarding better PML prognosis 
and survival.12, 13 The co-localization of CD8+ T cells with JCV-infected glial cells 
corroborated the significance of CD8+ T cells in PML.14, 15 However, the frequent 
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occurrence of PML during HIV infection, its occurrence in idiopathic CD4+ 
lymphopenia, the association of HLA class II alleles with JCV-specific T cell 
responses and the analysis of brain-infiltrating T cells in PML-IRIS all suggest that 
CD4+ T cells also play an important role in controlling JCV infection.16-21 Our analysis 
of brain-infiltrating lymphocytes in natalizumab-associated PML-IRIS demonstrated 
highly abundant and clonally expanded JCV VP1-specific CD4+ T cells, which deploy 
a broad spectrum of different strategies to mount an efficient JCV-specific immune 
response.16, 17  
Here, we report that JC viral persistence in the CNS may occur even after immune 
reconstitution and despite intrathecal JCV-specific T cell and antibody responses. 
Detailed analysis of the brain-infiltrating T cell subpopulations at onset of IRIS 
demonstrated differential antigen specificities with CD8+ T cells strongly responding 
to conserved JCV epitopes and CD4+ T cells mainly directed against VP1, where 
mutations are most frequently observed. Finally, we show that mutations of VP1 
compromise the CD4+ T cell response and that CD8+ T cell responses decline in 
parallel. Our data suggest that efficient CD4+ T cell recognition of neurotropic JCV 
variants is required to support JCV-specific CD8+ effector T cells in eliminating JCV 
from the brain. 
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MATERIALS AND METHODS 
Ethics statement and patient information 
We collected blood and cerebrospinal fluid (CSF) from four patients with multiple 
sclerosis and concomitant natalizumab-associated or PML (patients 1-3) or GCN 
(patient 4) and additionally a brain biopsy from patient 4 for diagnostic reasons. 
Collection of human samples for research purposes was approved by the Cantonal 
Ethical Committee of Zürich, Switzerland (EC-ZH-No. 2013-0001). Samples were 
obtained with written informed consent of patients.  
Patient 1 (male, 44 years old) was diagnosed with PML in June 2014 after incidental 
finding of asymptomatic left temporal lesions suspicious for PML and subsequent 
detection of JCV DNA in CSF. Four weeks after plasmapheresis, he complained of 
fatigue and verbal memory deficits corresponding to deterioration of EDSS from 1.5 
to 2.0, and MRI showed contrast enhancement within the PML lesion, indicating 
PML-IRIS. After starting corticosteroid therapy, fatigue and verbal memory deficits 
improved permanently. In February 2015, no JCV DNA was detectable in CSF (Fig. 
1), and MRI showed marked atrophy of the PML lesion with slight punctiform contrast 
enhancement, but no perilesional edema and no diffusion restriction, confirming 
successful remission from PML. 
Patient 2 (male, 46 years old) developed progressive hypesthesia in both feet and 
hands in July 2012. MRI surprisingly showed new confluent T2-hyperintensive 
lesions in the right temporal and frontal region and smaller T2 lesions in the left uncal 
region and internal capsule. Subsequent CSF analysis proved PML by detection of 
JCV DNA. Four weeks after plasmapheresis he developed headache and 
progressive left sensorimotor hemisyndrome with typical MRI signs of PML-IRIS, 
leading to severe gait impairment and wheelchair-dependency. Corticosteroid 
treatment gradually improved the left hemiparesis enabling unrestricted ambulation 
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by October 2012 and resulting in a residual state of mild left facio-brachial 
sensorimotor hemiparesis by February 2013. MRI showed marked atrophy of the 
PML lesions with few contrast-enhancing spots and no edema, and JCV DNA was 
undetectable in CSF in August 2013 (Fig. 1), confirming successful remission from 
PML. 
In patient 3 (female, 45 years old), PML was diagnosed in May 2013 because of 
progressive right hemiparesis and dysarthria, detection of T2-hyperintense lesions in 
the left precentral gyrus, left thalamus and internal capsule and both cerebellar 
peduncles in MRI and detection of JCV DNA in CSF. Two weeks after 
plasmapheresis, right hemiparesis and dysarthria started to worsen (change from 
EDSS 4.0 to EDSS 9.0 within two weeks). Intense intralesional contrast 
enhancement was detected by MRI and PML-IRIS was diagnosed. After starting 
corticosteroid treatment EDSS improved to 7.5 until October 2013. MRI showed less 
contrast enhancement, but enlargement of left precentral and thalamic lesions, 
indicating PML progression. Corticosteroid treatment was stopped in February 2014. 
In June 2014, the right hemiparesis worsened because of further PML progression as 
indicated by diffusion restriction in the periphery of the left precentral lesion, but 
stabilized again until September 2014 with no further change in neurological deficits 
until March 2015 (EDSS 7.5). Repeated CSF analysis between July 2013 and March 
2015 revealed persistence of JCV DNA 21 months after PML-IRIS. Therefore, the 
patient was designated “JCV non-clearer”. 
Patient 4 (female, 32 years old) was diagnosed with GCN in March 2012 because of 
progressive truncal and limb ataxia, MRI-proven cerebellar atrophy and detection of 
JCV DNA in CSF.22 By then, she needed unilateral assistance to walk at least 50m, 
corresponding to EDSS 6.0. Until June 2012, her cerebellar deficits worsened 
continuously without a correlate of new PML-/GCN or MS lesions in MRI. Because 
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the clinical deterioration could not be attributed to GCN progression or IRIS, a 
diagnostic cerebellar biopsy was collected from the right cerebellar hemisphere, 
showing histopathological signs of GCN-IRIS. At this time, she was restricted to 
wheelchair and needed help in transferring to the bed, corresponding to EDSS 7.5. A 
single corticosteroid pulse therapy induced no changes, but gait ataxia improved 
slowly until May 2014, enabling her to walk maximally 40m without assistance (EDSS 
6.5). 23 months after PML-IRIS, no new lesions were detectable in MRI, but CSF 
analysis showed 32 JCV copies/ml (Fig. 1), consistent with “JCV non-clearer” status. 
 
CNS tissue and peripheral blood processing  
CSF-derived mononuclear cells were collected from diagnostic spinal taps, and 
PBMCs were separated by Ficoll density gradient centrifugation (PAA, Austria). A 
diagnostic brain biopsy of the GCN patient was taken from the right cerebellar 
hemisphere at onset of IRIS, from which a part was provided for research purposes. 
CNS tissue was processed immediately after surgery, as previously described.16 
 
Expansion of mononuclear cells and generation of T cell clones (TCC) 
Brain- and CSF-derived mononuclear cells were expanded as bulk populations with 1 
µg/ml phytohaemagglutinin (PHA, Sigma, USA) and human IL-2 (kindly provided by 
Federica Sallusto, Bellinzona, Switzerland) as previously described.16 Expanded 
brain CD4+ were sorted on a FACSAria (BD) after staining for CD4 and CD8. TCC 
were generated by flow cytometry-based sorting of anti-TCR Vβ21.3/22-labeled T 
cells and subsequent cloning by limiting dilution conditions using the above described 
expansion protocol. Antibodies used in the study are listed in Supplementary Table 1.   
 
PCR 
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JCV copy numbers in CSF were kindly determined by the Virology Institute of the 
University Zurich (samples with >200 copy numbers/ml) or at the Laboratory of 
Molecular Medicine and Neuroscience (NIH) (samples with <200 copy numbers/ml) 
using a quantitative PCR specific for JCV large T antigen (LTAg). The genome of the 
JCVGCN8 variant (GenBank accession no. KM225765) from the cerebellar biopsy was 
identified by amplifying from extracted brain-derived DNA and sequencing multiple 
overlapping PCR fragments (400-700 bp) covering the whole JCV genome. Primers 
were obtained from Microsynth (Supplementary Table 2). 
 
Flow cytometric analysis 
For intracellular cytokine staining (ICS) of T cells, stimulation was performed either 
with 50 ng/ml phorbol myristate acetate (PMA) and 1 µg/ml Ionomycin (Sigma) or 
specific peptide in the presence of Golgi-Plug (BD). After 5 h cells were stained with 
Live/Dead® Fixable Aqua Dead Cell Stain Kit (Invitrogen, USA), fixed and 
permeabilized with Cytofix/Cytoperm Kit (BD) and subsequently stained with 
fluorescently labeled antibodies. Measurements were performed on a LSR Fortessa 
Flow Cytometer (BD) and data was analyzed with FlowJo (Tree Star, USA). Heat 
maps were generated using Spice (NIH, NIAID, USA) software. 
 
JCV VP1 ELISA 
The level of JCV VP1/VLP-specific IgG antibodies was determined as described 
previously.20 Briefly, ELISA plates were coated with 200ng of the JCV VLP per well 
and incubated with CSF (1:2, 1:10, 1:100 and 1:1000 dilutions). Human IgG was 
detected using biotin-conjugated anti-human IgG-Fc antibody and avidin horseradish 
peroxidase (eBioscience, Frankfurt, Germany). Optical density at 450nm (OD450) was 
measured with a Synergy H1 microplate reader (BioTek, Lucerne, Switzerland). 
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Antibody reactivity was assessed in arbitrary units (AU) using a standard curve 
obtained from a serial dilution of a standard serum for interpolating ODs by four 
parameter logistic curve fit.  
 
JCV epitope mapping 
166 JCV peptides (13-16-mer) with an overlap of five amino acids covering the JCV 
proteome were arranged in a set of 36 pools with each pool containing up to five 
peptides. All peptides were obtained from Peptides and Elephants (Germany, 
Supplementary Table 3). 2x104 PHA-expanded brain- or CSF-derived T cells were 
co-cultured with 1x105 irradiated autologous PBMC and peptide pools (2 µM per 
individual peptide) per well in X-Vivo. After 48 h, culture supernatants were analyzed 
for the release of IFN-γ using ELISA (Biolegend, USA) and cells were further 
incubated with medium containing IL-2. Five days later, cells were restimulated with 
the identical peptide pools and 5x104 autologous EBV transformed B cells per well in 
the presence of Golgi-Plug (BD) followed by ICS as described above. Autologous 
EBV-transformed B cell lines were generated from PBMCs using the supernatant of 
the EBV-producing marmoset B cell line B95-8 and OKT3 antibody and were 
maintained in RPMI 1640 medium supplemented with 10% FCS.  
Antigen-specificity of individual TCCs was tested by using irradiated autologous 
PBMC and peptide pools or individual peptides at different concentrations. Additional 
blocking experiments of CD4 and CD8 co-receptors were performed by incubating 
prior to peptide stimulation with either a blocking antibody (5 µg/ml) for CD4 (clone 
RPA-T4) or CD8 (clone SIDI8BEE). After 48 h, culture supernatants were analyzed 
for the release of granzyme B, IFN-γ and TNF using ELISA Kits (Biolegend, USA or 
Mabtech, Sweden). 
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Stimulation with freeze-thawed lysates  
A plasmid coding for JCVMAD1 VP1, VP2 and VP3 (kindly provided by Akira 
Nakanishi, Aichi, Japan)23 was used to substitute the VP1MAD1 sequence with the 
VP1GCN8 sequence identified in patient 4. The plasmids were transfected into 293TT 
cells with Lipofectamine 2000 (Invitrogen). After 48 h, cells were harvested, 
controlled for transfection efficiency and lysed with repetitive cycles of freeze-thaw 
treatment. Freeze-thawed lysates were then co-cultured with autologous irradiated 
PBMCs (1x105 cells/well) in X-Vivo for 4 h to allow appropriate uptake and antigen 
presentation. Thereupon, expanded brain-derived CD4+ T cells (2x104 cells/well) 
were added. After 48 h, cell culture supernatants were taken to determine IFN-γ 
release by ELISA (Biolegend). Furthermore, competition assays were performed by 
incubating autologous irradiated PBMCs for 4 h with freeze-thawed lysates 
containing VP1MAD1 and then adding peptides pools (8 peptides with 1 amino acid 
overlap, 1 µM per each individual peptide) covering the C-terminal region of either 
VP1MAD1 or VP1GCN8. After pre-incubation with peptides for 1 h sorted brain CD4+ T 
cells were added and secretion of IFN-γ evaluated as described above. 
 
TCR analysis  
The TCR Vβ repertoire of PHA-expanded cells was quantitatively determined by flow 
cytometry using anti-TCR Vβ antibodies in combination with antibodies against CD4 
and CD8 (Supplementary Table 1). Sequencing of TCR rearrangements and CDR3 
length spectratyping was performed and analyzed as previously described.17 
 
Statistical analysis 
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Statistical analyses were performed with paired Student`s t test (Microsoft Excel). P 
values of < 0.05 were considered as statistically significant. 
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RESULTS 
Delayed elimination of neurotropic JCV despite immune reconstitution  
During clinical monitoring of four MS patients, who developed clinical manifestations 
of JCV infection in the CNS (patients 1-3 with PML and patient 4 with GCN) during 
natalizumab treatment, we observed an unusually slow elimination of JCV in the CSF 
in two patients (Fig. 1A). In contrast to patients 1 and 2, who cleared JCV rapidly and 
showed MRI-proven and clinical remission of PML, JCV non-clearers (patient 3 and 
4) still disclosed detectable amounts of JCV after 21 (patient 3) or even 23 months 
(patient 4) and had a worse clinical outcome after one year despite the occurrence of 
IRIS. IRIS was diagnosed in all cases based on acute worsening of PML- or GCN-
related symptoms, and MRI contrast enhancement of PML-lesions or biopsy-proven 
immune infiltration of JCV-infected tissue. Increasing cell counts and anti-JCV VP1 
antibody levels in the CSF also supported the presence of immune reconstitution in 
the CNS (Fig. 1B and 1C).  
Since IRIS is characterized by strong infiltration of T cells, we further evaluated the 
responses of CNS-infiltrating T cells to the JCV major capsid protein VP1 at onset of 
IRIS. Whereas CNS-infiltrating T cells of JCV clearer (patient 1 and 2) revealed IFN-γ 
responses to VP1, we observed a lack of VP1-specific responses and an overall low 
level of IFN-γ secretion upon PHA stimulation in JCV non-clearer patient 3 (Fig. 1D) 
indicating an insufficient T cell response to JCV. Surprisingly, CNS-infiltrating, in 
particular brain-infiltrating T cells of JCV non-clearer patient 4 displayed strong IFN-γ 
responses to VP1 (Fig. 1D). However, JC viral load dropped only slowly. Interestingly 
this patient was diagnosed with GCN 22, a clinical manifestation of JCV infection, in 
which knowledge about immune surveillance and clearance mechanisms still remain 
scarce.  
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Absence of strong Th1-mediated CD4+ T cell response to JCV antigens in a 
patient with persistent JCV infection  
Detailed characterization of the CSF-derived T cell infiltrate revealed the presence of 
CD4+ T cells, CD8+ T cells and a subpopulation of CD4dimCD8+ T cells which have 
been reported to represent activated CD8+ T cells33 (Fig. 2A). CD4+ T cell numbers 
were increased in the JCV clearer patients 1 and 2 compared to the JCV non-clearer 
patients (Fig. 2A). In all patients, the T cell subsets exhibited an overall predominant 
Th1/Tc1 cytokine profile in the CSF, although a part of the infiltrating T cells 
expressed also a bifunctional Th1-2 phenotype (IFN-γ+ IL-4+) (Fig. 2B). Among the 
subsets, CD4dimCD8+ T cells secreted the largest amount of the proinflammatory 
cytokines IFN-γ and TNF in all 4 patients, which points at an important role of this 
subpopulation during viral clearance. However, in contrast to the other patients JCV 
non-clearer patient 3 showed a marked decrease of IFN-γ+CD4+ T cells during follow-
up explaining the insufficient IFN-γ secretion in response to VP1 (Fig. 2B). 
To determine the specificity of the CSF-infiltrating T cells we performed epitope 
mapping using 36 peptide pools covering the whole proteome of the prototypic 
JCVMAD1 strain. The CSF T cell infiltrates revealed strong CD4+ T cell responses to 
selective JCV antigens in patient 1, 2 and 4, whereas responses to JCV epitopes in 
JCV non-clearer patient 3 were only very weak or even absent indicating an 
inefficient immune control of JCV in this patient. Whereas CSF-infiltrating CD4+ T 
cells of patient 1 preferentially responded to LTAg epitopes and VP1 peptide pools 4 
and 10, CD4+ T cells of patient 2 and 4 were primarily stimulated by VP1 epitopes. In 
contrast to the clear responses in CD4+ T cells, the responses of CSF-infiltrating 
CD8+ T cells were weak in all four patients. Furthermore, at the time of peak 
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responses, CD8+ T cells and CD4+ T cells from each patient targeted different JCV 
epitopes. 
 
Brain-infiltrating T cell subsets are directed against different JCV proteins  
In order to understand the long-term persistence of JCV in patient 4 (GCN) despite 
experience of IRIS and strong T cell recognition of JCV VP1, we characterized in 
detail the functional phenotype and antigen specificity of the brain-infiltrating T cell 
populations due to the availability of a diagnostic brain biopsy at onset of GCN-IRIS. 
The inflammation was characterized by a prominent T cell infiltrate consisting of 
CD8+ T cells (66%), to a lesser extent of CD4+ T cells (24%) and CD4dimCD8+ T cells 
(5.2%) (Fig. 3A and 3B).  
We then further determined the fine specificity of the brain-infiltrating T cells by 
performing JCVMAD1 epitope mapping. Overall, brain-derived bulk T cells recognized 
most of the peptide pools and thereby several epitopes encoded by all six open 
reading frames of JCV (Fig. 3C). Nevertheless, responses were considerably 
stronger to peptide pools 3-10 covering almost the entire VP1 protein with exception 
of peptide pool 11, which consists of the C-terminal region of VP1. Re-stimulation of 
the brain-infiltrating T cells with the JCV peptide pools and subsequent ICS for IFN-γ 
allowed us to separate the responses of CD4+, CD8+ and CD4dimCD8+ T cells (Fig. 
3D). Surprisingly, CD4+ and CD8+ T cell responses differed clearly in their JCV 
recognition pattern. Whereas the response of IFN-γ+ CD4+ T cells was mainly 
directed against peptide pools in VP1 and small T antigen (sTAg), CD8+ T cells 
primarily responded to several epitopes derived from VP2/3 and large T antigen 
(LTAg) (Fig. 3D). Interestingly, responses of CD4dimCD8+ T cells (activated CD8+ T 
cells) were very strong amongst the CD8+ T cell responses.  
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Clonal expansion of activated CD8+ T cells that co-express CD4   
Compared to conventional CD8+ T cells, CD4dimCD8+ T cells are often found in 
increased numbers in chronic infections, display an activated phenotype and mediate 
strong antiviral immunity against multiple viruses.24-26 However, their function is as 
yet poorly understood and since this subpopulation has so far not been reported in 
JCV-associated CNS diseases, we examined their capacity for viral clearance. 
Immunostaining of freshly isolated mononuclear cells from the cerebellar tissue 
demonstrated the abundant presence of infiltrating CD4dimCD8+ T cells with an 
activated effector memory phenotype according to the expression of the activation 
markers HLA-DR and CD38 (Fig. 4A).  
Further characterization of the TCR Vβ repertoire revealed a massive expansion of a 
fraction of CD4dimCD8+ T cells in the brain since the expression of two TCR Vβ-chain 
families, Vβ22 and Vβ21.3, made up 83% of this subset and more than 4% of the 
whole T cell infiltrate (Fig. 4B). To identify individual TCCs within the above 
population, we sorted brain CD4dimCD8+ T cells for the two prominent TCR Vβ-chains 
21.3 and 22, and by using TCR Vβ CDR3 spectratyping and sequencing we 
confirmed clonal expansions of three distinct CDR3 sequences (Fig. 4C). Since it has 
been reported that CD4dimCD8+ T cells originate from CD8+ T cells, which can 
transiently express the CD4 receptor after stimulation 27, we proved that CD4dimCD8+ 
TCCs arise from the single CD8+ but not CD4+ T cell compartment by using a PCR 
specific for the identified TCR Vβ-chains of CD4dimCD8+ TCCs (Fig. 4D). 
 
Activated CD8+ T cells recognize antigen with high affinity and mount Tc1 
responses to conserved LTAg epitopes 
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Extraction of genomic DNA from the cerebellar biopsy of patient 4 (229 JCV DNA 
copies/cell) enabled us to identify a single novel JCV strain (GenBank no.: 
KM225765), which contained three deletion sites within LTAg and VP2/VP3 
compared to the sequence of the prototypic JCVMAD1 strain (Fig. 4E). Mapping of the 
target epitope of one of the three most prominent CD4dimCD8+ TCCs showed strong 
recognition of peptide pool 27, which consists of conserved epitopes in LTAg (Fig. 
4F) and matched with the recognition pattern of bulk brain CD4dimCD8+ T cells 
responding overall to conserved epitopes in LTAg and VP2/VP3 (Fig. 3C). Only one 
peptide in pool 27, LTAg357-370, stimulated the secretion of IFN-γ even at very low 
concentrations demonstrating high affinity recognition by the TCC (Fig. 4G). 
Stimulation with LTAg357-370 resulted in secretion of the proinflammatory Tc1 
cytokines IFN-γ and TNF as well as high levels of granzyme B suggesting strong 
cytotoxic potential (Fig. 4H). All responses to LTAg357-370 were dependent on the CD8 
co-receptor but not CD4 as shown by competition with specific blocking antibodies 
(Fig. 4H), supporting that the TCC functionally belongs to the CD8+ T cell 
compartment.  
 
Mutations of JCVGCN8 VP1 compromise the CD4+ T cell response leading to a 
decline of CD8+ T cell responses 
As shown above, brain-infiltrating CD4+ T cells preferentially responded to VP1 
epitopes. Therefore, we addressed the response of CD4+ T cells against the 
autologous neurotropic JCVGCN8 strain, which upon sequencing revealed multiple 
mutation sites in the coding region of VP1 compared to the prototypic JCVMAD1 strain 
(Fig. 5A). Noticeably, an in-frame deletion of six nucleotides led to the loss of a 
glutamine and a threonine in the C-terminal end of VP1, which is consistent with the 
characteristic mutation pattern found in VP1 of other JCVGCN strains.28, 29  
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We developed a stimulation assay using lysates of 293TT cells transfected with 
plasmids coding for VP1MAD1 or VP1GCN8 that allowed us to study the brain CD4+ T 
cell responses to distinct JCV VP1 variants (Fig. 5B and 5C). Lysates of cells 
transfected with VP1MAD1 and VP1GCN8 stimulated IFN-γ secretion of purified brain 
bulk CD4+ T cells (Fig. 5D). However, IFN-γ secretion was significantly lower in 
response to VP1GCN8, suggesting that JCVGCN8 mutations most likely affect 
recognition of critical epitopes by brain-infiltrating T cells or result in a partial agonist 
or antagonist TCR ligands. Titration of both lysates showed clear dose-dependent 
responses (Fig. 5E).  
Based on these observations we further tested the CD4+ T cell recognition of 
individual JCVGCN8 epitopes, in which mutations were found. Among these epitopes 
only one peptide, namely VP1123-137, induced an IFN-γ response in brain CD4+ T cells 
(data not shown). Interestingly, the variant peptide VP1123-137T128A, in which a 
threonine at position 128 was substituted with alanine according to the mutation 
found in JCVGCN8, showed significantly less IFN-γ secretion than the peptide with the 
prototypic MAD1 sequence (Fig. 5F). These differences remained at decreasing 
peptide concentrations, however, they do not sufficiently explain the poor recognition 
of JCVGCN8. Since peptides spanning all three other mutated areas in VP1 did not 
induce any response alone, we examined a possible antagonistic effect on CD4+ T 
cell responses using VP1MAD1 lysates in the presence of competitor peptides covering 
the area of VP167-82, VP1151-165 and VP1331-352 of either JCVMAD1 or JCVGCN8. Only 
peptides spanning the C-terminal end of VP1GCN8 331-352, led to a reduction of IFN-γ 
secretion by CD4+ T cells in response to VP1MAD1 lysate stimulation compared to a 
control pool of peptides spanning the C-terminal area of VP1MAD1 333-354 (Fig. 5G).  
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These results suggest that peptides within the C-terminus of JCV VP1GCN8 mediate 
additional inhibitory effects. 
Since CD4+ T cells are known to orchestrate efficient CD8+ T responses, we finally 
analyzed, if CD8+ T cell responses to LTAg changed with onset of IRIS and after 
IRIS. Interestingly, CSF-infiltrating T cell responses to a peptide pool covering the 
entire LTAg dropped significantly after IRIS despite the capacity to secrete 
comparable levels of IFN-γ after PHA stimulation (Fig. 5H). The drop in responses to 
LTAg was accompanied by a decline of CD8+ and CD4dimCD8+ T cell numbers five 
months after IRIS (Fig. 5I). This observation most likely accounts for the inefficient 
viral clearance in this patient (Fig. 6). 
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DISCUSSION 
At present it is not known, which factors are most important to clear JCV from CNS in 
PML and GCN efficiently. The prominent T cell infiltrate during PML-IRIS and GCN-
IRIS points to a crucial role of brain-infiltrating T cells in eliminating JCV from the 
brain.16, 22, 30 Importantly, the presence of both CD4+ and CD8+ T cells were 
described in brain biopsies of PML-IRIS and GCN-IRIS cases, indicating that both 
subpopulations are relevant for controlling JCV infection in the CNS.16, 22, 30 However, 
several studies reported dominant CD8+ T cell infiltrates in the brain during PML-IRIS 
14, 30,  but either lacked evidence for the presence of CD4+ T cells or were performed 
in AIDS patients. Recent data on intracerebral immune responses in PML-IRIS 
disclosed massive upregulation of HLA-class II in the brain, clonal expansion of CD4+ 
T cells and a variety of strategies used by CD4+ T cells to efficiently clear JCV from 
infected glial cells.16, 17 However, the knowledge about the function and specificity of 
brain-infiltrating T cells during JCV infection is still limited. 
Interestingly, recent studies reported JC viral persistence in a subgroup of PML 
patients despite immune reconstitution9, 10 questioning the role of T cells in this 
subcohort. Here we describe in two out of four natalizumab-associated PML/GCN 
patients JC viral persistence over 21 month despite development of IRIS. Evaluation 
of the immune reconstitution in a JCV non-clearer PML patient revealed absence of 
reactivity to VP1 as well as a generally very weak CD4+ T cell response to other JCV 
antigens and an overall low secretion of IFN-γ in the CSF-infiltrating CD4+ T cell 
compartment, indicating why the immune response to JCV in the CNS may have 
been inefficient. Surprisingly, another JCV non-clearer, who suffered from GCN, 
remained JCV DNA-positive in the CSF after 2 years despite occurrence of 
pathologically prominent IRIS, strong recognition of VP1MAD1 by brain-infiltrating T 
cells and increased intrathecal synthesis of VP1-specific antibodies.  
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The availability of brain tissue of the GCN patient enabled us to examine in detail 
viral and immunological aspects of the brain infiltrate to explore potential reasons for 
incomplete elimination and persistence of JCV in the CNS. The novel JCVGCN8 
variant of this patient showed GCN-type mutations in the C-terminal region of VP1, 
consistent with recently reported JCVGCN variants in a second case of natalizumab-
associated GCN and previously reported JCVGCN strains.28, 29, 31 Epitope mapping of 
brain-infiltrating T cells revealed differential antigen specificity among the 
subpopulations and strong responses to VP1MAD1 epitopes. Whereas CD4+ T cell 
responses were specifically directed against VP1MAD1 and sTAgMAD1, CD8+ T cells 
primarily responded to several epitopes derived from VP2/3MAD1 and LTAgMAD1. The 
difference in epitope recognition between CD4+ and CD8+ T cell subsets may have 
several explanations including the fact that both subsets are restricted by different 
classes of HLA molecules and the expression of these on different target/antigen 
presenting cells with distinct antigen-processing pathways. By choosing an overlap of 
5 amino acids between the peptides, we may have missed potential epitopes. 
However, a recent study on JCV epitope mapping using the same JCV peptide pools 
revealed that a wide range of different epitopes is recognized, that responses to all 
JCV peptide pools were detected and that there was high variability of reactivity 
against single JCV peptide pools between different individuals suggesting that the 
15-mer peptides used in this work should be sufficient to uncover variability in epitope 
specificity.20 
The preferential expression of LTAg in granule cell neurons32 suggests that CD8+ T 
cells are the main effector cells for eliminating JCVGCN-infected granule cell neurons. 
Interestingly, a large portion of the JCV-specific CD8+ T cell responses was driven by 
an activated, highly abundant and clonally expanded CD8+ effector T cell 
subpopulation, which co-expresses CD4. The identification of the most relevant TCR 
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sequences of CD4dimCD8+ T cells in the CD8+ T cell compartment of the cerebellum 
demonstrated that this subset originates from CD8+ progenitors and upregulates CD4 
inside the CNS. The upregulation of CD4 on CD8+ T cells can be induced by strong 
activation and has been shown to be involved in interacting with HLA-class II, IL-16-
induced chemotaxis and enhanced effector functions.25, 33 Functional studies with 
one of the prominent brain-derived CD4dimCD8+ TCCs revealed CD8-dependent 
recognition of a LTAg epitope with high affinity, Tc1 profile and cytotoxic potential. 
Since blocking of the CD4 receptor in the CD4dimCD8+ TCC did not alter the response 
to the peptide, and since CD4 is known to serve as a receptor for soluble IL-1633, we 
expect that co-expression of CD4 is primarily serving a role in chemotactic 
recruitment of CD4dimCD8+ T cells to the site of inflammation in the cerebellum. 
Interestingly, granule cell neurons were reported to secrete soluble IL-16 upon 
caspase-3 cleavage of neuronal IL-16 (NIL-16), a variant of the IL-16 precursor.34 We 
assume that the presence of cerebellar granule cell neuron-derived IL-16 favors the 
migration and/or maintenance of CD4dimCD8+ T cells into the brain. Although there is 
growing evidence for an important role of CD4dimCD8+ T cells in antiviral defense, 
their functional importance remains unclear.24, 26 Here, we corroborate their important 
role as effector cells in targeting JCV-infected granule cell neurons by detecting 
marked expansion of mainly three TCCs in the brain, exquisite specificity to 
conserved JCV epitopes and Tc1 phenotype. The mechanisms of clearing JCV-
infected neurons likely involves antigen-specific cytotoxicity via release of lytic 
granules containing granzyme B as we demonstrated for the CD4dimCD8+ TCC upon 
stimulation with the target LTAg antigen, but could also involve other antigen-
independent mechanisms.35 
Noteworthy, JCV viral load dropped relatively slowly in the CSF of the GCN patient 
despite the presence of LTAg-specific CD8+ effector T cells. Since JCVGCN variants 
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infect neurons that lack MHC class II expression 35, they may evade direct 
recognition by CD4+ T cells. Nevertheless, CD4+ T cells were present in the 
cerebellar infiltrate and still are expected to play an important role in orchestrating an 
efficient T and B cell response by recognizing JCV epitopes of phagocytosed JCV 
virions on antigen-presenting cells (APC). However, the presence of multiple 
mutations in VP1 of JCVGCN8 might impede efficient immune responses, since viral 
variations can affect neutralization by antibodies or generate naturally occurring viral 
peptide variants, known as altered peptide ligands, that prevent activation of T 
cells.36 To date, mutations in VP1 were only considered to affect the host receptor 
binding of JCV.7  
Comparative antigen presentation of VP1MAD1 and VP1GCN8 peptides using lysates 
resulted in reduced IFN-γ responses of brain CD4+ T cells to VP1GCN8, indicating 
compromised recognition of mutated VP1 epitopes. Indeed, a variant VP1 epitope 
containing T128A of JCVGCN8 failed to induce full IFN-γ secretion compared to the 
corresponding epitope of VP1MAD1 indicating less efficient recognition of VP1GCN8 by 
cerebellum-derived CD4+ T cells. Since CD4+ T cells did not respond to any of the 
other mutated VP1 epitopes, we investigated a possible antagonistic or competitive 
effect by these peptides, and indeed, the addition of peptides covering the C-terminal 
mutations of JCVGCN8 led to reduced CD4+ T cell responses. Based on the higher 
predicted binding affinities of C-terminal VP1GCN8 peptides (data not shown), we 
assume that the less efficient response to the JCVGCN8 VP1 epitopes is at least in 
part due to competition for HLA-DR binding. Both mechanisms, i.e. reduced 
recognition of JCVGCN8 T128A and competition mediated by C-terminal epitopes of 
VP1GCN8, might contribute to the slow elimination of JCVGCN8. The mutation-driven 
CD4+ T cell escape by the JCVGCN8 resulted not only in inefficient effector functions 
like IFN-γ secretion but probably also in impaired support for CD8+ T cells, since 
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CD8+ and CD4dimCD8+ T cells as well as reactivity to LTAg declined dramatically 
after IRIS. A potential causal relationship between JCV-specific CD4+ and CD8+ T 
cells in the brain is likely based on the supportive functions of CD4+ T cells via 
secretion of critical cytokines that maintain the survival, expansion and response of 
CD8+ T cells, as shown previously in the context of other viral infections.37, 38 
Our data provide novel information on host-pathogen interactions during CNS 
infection with JCV and illustrate alongside with the recently described antibody 
“recognition holes” for JCV variants in natalizumab-associated PML39 now for the first 
time also JC viral evasion mechanisms of T cell immunity driven by specific 
mutations in the viral genome during persistent JCV infection. Based on these 
observations we hypothesize that efficient CD4+ T cell recognition of neurotropic JCV 
variants is crucial to support CD8+ T cells for eliminating JCV infection of the CNS 
and prevent JC viral persistence (summarized in Fig. 6). Clinicians should be aware 
of relevant JCV mutations beyond the non-coding region. We recommend whole JC 
viral genome sequencing in cases of JCV persistence in CSF after PML-IRIS and 
concomitant studies on JC viral CNS immunity. Further research in this area should 
teach us more about the involvement of JCV variants in immune escape mechanisms 
in the brain and in general regarding immunity against viral infections in the CNS. 
Finally, this knowledge should help us to develop strategies to overcome JC viral 
immune evasion in these patients. 
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FIGURE LEGENDS 
 
Figure 1. Delayed clearance of JCV in the CSF of natalizumab-associated JCV 
infection despite immune reconstitution. (A) JC viral load in CSF during course of 
JCV infection measured by quantitative PCR. (B) Cell numbers in CSF during course 
of JCV infection. (C) CSF antibody responses of natalizumab-associated PML 
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patients to JCV VP1, expressed as AU. (D) PHA-expanded brain- or CSF-derived T 
cells from time point of IRIS were tested for reactivity to VP1MAD1 and PHA using 
autologous APCs. Results show the mean IFN-γ secretion from four replicates +/- 
SEM.  
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Figure 2. CSF-infiltrating T cells show a prominent Th/Tc1 phenotype with 
strong CD4+ T cell responses to selective JCV antigens. (A) Composition of T cell 
subsets in the CSF infiltrate of all 4 patients at time point of IRIS. (B) Cytokine profile 
of brain CD4+, CD8+ and CD4dimCD8+ T cells upon stimulation with PMA/Ionomycin 
depicted as heat map. The percentage of positive cells is illustrated with a color 
gradient. (C) ICS of CSF-infiltrating T cells of all 4 patients. The graphs indicate the 
percentage of IFN-γ+ cells in the CD4+ (red) and CD8+ (blue) T cell compartment after 
restimulation with JCV peptide pools. The grey dotted line indicates the frequency of 
IFN-γ+ cells under unstimulated conditions, depicted as Ø. Prior gating included 
singlets, live and CD3+ cells. 
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Figure 3. Epitope mapping of brain-infiltrating T cells reveals differential 
antigen specificity during neuronal JCV infection. (A) Infiltration of CD4+ (brown) 
and CD8+ (red) T cells in the cerebellum of patient 4, who developed GCN. (B) 
Composition of T cell subsets in the brain infiltrate of patient 4 at time point of GCN-
IRIS. (C) IFN-γ response of brain-derived T cells from the GCN-IRIS patient against 
36 peptide pools spanning all open reading frames of JCV. Results show the mean of 
IFN-γ secretion from four replicates +/- SEM. Values below standard range are 
indicated as not detectable (n.d.) and unstimulated conditions by Ø. (E) (D) ICS of 
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brain-infiltrating T cells. The graphs indicate the percentage of IFN-γ+ cells in the 
brain CD4+ (red), CD8+ (blue) and  activated CD8+ (corresponds to CD4dimCD8+) 
(purple) T cell compartment after restimulation with JCV peptide pools. Prior gating 
included singlets, live and CD3+ cells. 
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Figure 4. Activated CD8+ T cells are enriched, clonally expanded and exhibit 
Tc1 responses against conserved LTAg epitopes. (A) Phenotyping of activated 
CD8+ T cell subset in freshly isolated brain infiltrate during GCN-IRIS. (B) TCR Vβ-
chain distribution among expanded brain-infiltrating activated CD8+ (CD4dimCD8+) T 
cells using TCR Vβ-chain-specific antibodies in flow cytometry. (C) Analysis of sorted 
TCR Vβ21.3+ or TCR Vβ22+ CD4dimCD8+ T cells for clonal expansion by CDR3 
spectratyping and sequencing. The respective CDR3 sequence is shown under the 
graph. (D) Fragments from PCRs specific for the CDR3 region, Vβ- and J-chain of 
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the most prominent TCR sequences from brain CD4dimCD8+ T cells using cDNA of 
bulk T cells, enriched single CD4+ or CD8+ T cells from the brain as input. (E) 
Scheme shows the location of amino acid mutations or deletions (del) in LTAg and 
VP2/VP3 of the identified cerebellar JCVGCN8 variant in comparison to JCVMAD1. (F-G) 
IFN-γ response of Vβ22+CD4dimCD8+ TCC against (F) JCV peptide pools and (G) the 
single peptide LTAg357-370 in a dose-dependent manner. (H) Secretion of cytokines by 
Vβ22+CD4dimCD8+ TCC in response to single peptide LTAg357-370 (0.1 µM) using 
ELISA.  The TCC was incubated prior to stimulation with either a blocking antibody 
for CD4 or CD8.  
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Figure 5. Mutations of JCVGCN8 VP1 modulate the JCV-specific CD4+ T cell 
response and result in a decline of LTAg-specific CD8+ T cells. (A) Scheme 
shows the location of amino acid mutations and deletions (del) in VP1 of the 
identified cerebellar JCVGCN8 variant in comparison to JCVMAD1. (B) Intracellular 
staining and (C) immunoblotting were used to control VP1 expression in 
untransfected (B, grey; C, 1), VP1MAD1- (B, black; C, 2) or VP1GCN8-transfected 293TT 
cells (B, black; C, 3). (D and E) IFN-γ response of PHA-expanded bulk brain CD4+ T 
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cells after co-culture with APCs preincubated with lysates of untransfected, VP1MAD1- 
or VP1GCN8-transfected 293TT cells. The ratio indicates the amount of cells used for 
lysis in relation to the amount of APCs. The dots represent replicates of tested wells 
(D) or the mean +/- SEM of six replicates (E). (F) IFN-γ response of brain CD4+ T 
cells to VP1123-137 (JCVMAD1) and VP1123-137T128A (JCVGCN8) peptides (10 µM) in a 
dose-dependent manner (mean of triplicates +/- SEM). (G) Competition assay using 
VP1MAD1-transfected 293TT cell lysates at different ratios and peptide pools covering 
the C-terminal end of VP1MAD1 or VP1GCN8. IFN-γ secretion is shown as mean of eight 
replicates (+/- SEM). Asterisks indicate significant differences (p value of < 0.05) 
using a paired t-test. (H) CSF-infiltrating T cell responses to LTAg, using a peptide 
pool covering the whole open reading frame of LTAg, as well as to PHA. (I) 
Distribution of CD8+ T cell subsets in expanded T cells from the CSF at onset of 
GCN-IRIS and after IRIS. 
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Figure 6. Overview of the role of CD4+ and CD8+ T cells in the clearance of JCV 
infection from the CNS. Mutations in the VP1 protein may generate altered peptides 
that escape efficient CD4+ T cell recognition resulting in inefficient Th1 effector 
functions. The latter affects cytokines like IFN-γ that induce upregulation of MHC 
molecules on the target cells as well as supportive cytokines like IL-2 and IL-21 which 
are known to maintain proliferation and survival of CD8+ T cells. Reduction of these 
cytokines might cause impaired support for JCV-specific CD8+ T cells that are crucial 
for eliminating JCV infection of the CNS. 
 
